INmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on Monday, March 30th.
MWN-AI** Summary
INmune Bio Inc. (NASDAQ: INMB), a clinical-stage biotechnology firm specializing in inflammation and immunology, is set to report its financial results for the year ending December 31, 2025. The company will host a conference call and webcast on March 30, 2026, at 4:30 PM ET to discuss these results and provide a corporate update. Stakeholders wishing to participate are advised to call in 5 to 10 minutes early using the provided dialing information. A live audio webcast will also be accessible online, with a replay available approximately three hours post-call.
Based in Boca Raton, Florida, INmune Bio focuses on harnessing the power of the innate immune system to tackle various diseases. The company operates through three primary product platforms: CORDStrom™, which utilizes human umbilical cord-derived mesenchymal stromal/stem cells; XPro™, a Dominant-Negative Tumor Necrosis Factor (DN-TNF) targeted therapy aimed at mitigating inflammation; and INKmune®, a cell-based treatment designed to enhance natural killer cell activity against cancer.
While the company is making strides in its clinical trials, it also cautions stakeholders about the uncertainties associated with drug development. INmune Bio emphasizes that the success of its products remains contingent on regulatory approvals and successful trial outcomes, and there are no guarantees regarding specific timelines or results.
As investors and analysts await the upcoming conference call, the outcomes of INmune Bio's clinical trials and financial performance over the past year will be pivotal in assessing the company’s prospects in the burgeoning field of immunotherapy. For further inquiries, David Moss, CEO, and Daniel Carlson, Head of Investor Relations, can be contacted directly.
MWN-AI** Analysis
As INmune Bio Inc. (NASDAQ: INMB) prepares to report its financial results for the year ended December 31, 2025, investors should closely monitor several key aspects during the upcoming conference call scheduled for March 30th, 2026, at 4:30 PM EDT. The performance of INmune Bio's product platforms—CORDStrom™, XPro™, and INKmune®—will be a significant focus, particularly as the biotechnology company operates in a competitive and rapidly evolving sector.
The company is positioning itself at the forefront of immunology and inflammation treatment. Investors should analyze the outcomes from the recent clinical trials, particularly with the CORDStrom™ platform which completed a trial in recessive dystrophic epidermolysis bullosa. Any positive results could signal significant market potential and drive stock prices higher.
Additionally, the status of the XPro™ platform, which aims to mitigate soluble TNF’s inflammatory effects, will be crucial to assess. Investors should pay attention to updates on regulatory approval status and any strategic partnerships that may enhance market entry. Progress on the INKmune® platform, designed to enhance natural killer cell efficacy against cancer, is also a vital area to evaluate, given the robust demand for innovative cancer therapies.
Financial performance metrics, especially revenue forecasts and R&D expenditure, will provide insight into the company's operational efficiency and funding sustainability. Challenges surrounding funding and drug production capabilities remain pertinent, as highlighted in past communications from management. Therefore, any updates on securing additional funding or strategic collaborations will be critical for future growth.
Overall, while the potential for INmune Bio is significant, investors should remain cautious of the inherent risks associated with clinical-stage biotech investments, particularly the uncertainty surrounding trial outcomes and regulatory approvals. Monitoring these factors closely will assist in making informed investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Management to host conference call and webcast at 4:30 pm ET on that day
Boca Raton, Florida, March 24, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company, today announced that it will host a conference call on Monday, March 30th, 2026 at 4:30pm EDT to discuss results for its year ended December 31, 2025, and to provide a corporate update.
Conference Call Information
To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Please ask for the INmune Bio First Quarter Conference Call when reaching the operator.
Date: March 30th, 2026
Time: 4:30 PM Eastern Time
Participant Dial-in: 1-800-343-4136 Participant Dial-in (international): +1-203-518-9843
Conference ID: INMUNE
A live audio webcast of the call can be accessed using this link or clicking here:
https://viavid.webcasts.com/starthere.jsp?ei=1748958&tp_key=96ca7c85d7
A replay will be available approximately 3 hours after the call through April 13, 2026 by dialing 1-844-512-2921 or 1-412-317-6671 (international) and entering PIN no. 11160807.
About INmune Bio Inc.
INmune Bio Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has three product platforms: (1) CORDStrom™, a proprietary pooled, allogeneic, human umbilical cord-derived mesenchymal Stromal/Stem cell (hucMSCs) platform that recently completed a blinded randomized trial in recessive dystrophic epidermolysis bullosa; (2) XPro™, a Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform designed to selectively neutralize soluble TNF, a key driver of inflammation and innate immune dysfunction; and (3) INKmune®, a cell-based medicine designed to prime a patient’s natural killer cells to eliminate minimal residual disease in patients with cancer. To learn more, please visit www.inmunebio.com.
Forward Looking Statements
Clinical trials are in early stages, and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release related to the development or commercialization of product candidates and other business and financial matters, including without limitation, trial results and data, including trial results, timing of key milestones, future plans or expectations, and the prospects for receiving regulatory approval or commercializing or selling any product or drug candidates, may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to several risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements because of these risks and uncertainties. CORDstrom™, XPro1595™ (XPro™, pegipanermin), and INKmune®™ have either finished clinical trials, are still in clinical trials or are preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA), the UK MHRA or any regulatory body and there cannot be any assurance that they will be approved by the FDA, the UK MHRA or any regulatory body or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements to reflect any event or circumstance that may arise after the date of this release.
Company Contact:
David Moss
Chief Executive Officer
(561) 710-0512
info@inmunebio.com
Daniel Carlson
Head of Investor Relations
(415) 509-4590
dcarlson@inmunebio.com
FAQ**
Can you provide an update on the progress of the CORDStrom™, XPro™, and INKmune® product platforms at INmune Bio Inc. INMB, particularly regarding any recent clinical trial results or milestones achieved?
What strategies is INmune Bio Inc. INMB implementing to secure additional funding for ongoing research and development, and how do these plans align with your corporate goals for 2026?
How does management at INmune Bio Inc. INMB plan to address any potential risks and uncertainties associated with FDA regulatory approvals for your product candidates?
In light of the ongoing clinical trials, how does INmune Bio Inc. INMB intend to communicate with investors about key developments and milestones throughout 2026?
**MWN-AI FAQ is based on asking OpenAI questions about INmune Bio Inc. (NASDAQ: INMB).
NASDAQ: INMB
INMB Trading
12.2% G/L:
$1.655 Last:
3,518,288 Volume:
$1.59 Open:
